Product-related press releases will only be available upon request after three weeks of publication on our website in order to comply with applicable regulation.

Novo Nordisk successfully completes phase 1b/2a trial with subcutaneous amycretin in people with overweight or obesity

Novo Nordisk expects its GLP-1 drugs Wegovy and Ozempic to soon come off the Food and Drug Administration’s official shortage list, CEO Lars Fruergaard Jørgensen told Barron’s on Wednesday ...

Get an overview of the Novo Nordisk press releases here or subscribe to our news and get it directly in your mailbox when we have news to tell. Disease areas Science & technology

Feb 5, 2024 · Novo Nordisk has agreed to acquire three manufacturing sites for $11bn, as the Danish drugmaker races to expand production of the weight loss drugs whose runaway success has sent the company’s...

Jan 4, 2024 · Novo Nordisk has signed deals worth up to $1bn with US biotech start-ups developing treatments for obesity and other cardiometabolic diseases, as the Wegovy manufacturer seeks to stay ahead in...

6 days ago · Novo Nordisk shares rose Wednesday after fourth-quarter earnings beat Wall Street's estimates, 2025 forecast came in line with expectations. Novo CEO Lars Fruergaard Jorgensen sees Wegovy supply ...

Jan 17, 2025 · Novo Nordisk stock skidded 5.3%, closing at 78.69. The news is a major blow to Novo Nordisk, whose semaglutide products are expected to generate $28.19 billion in 2024 sales. That...

Feb 12, 2024 · Novo Holdings, the controlling shareholder of Danish drugmaker Novo Nordisk, plans to invest up to $7bn annually by 2030, as dividend payments from the maker of diabetes drug Ozempic and weight...

Oct 21, 2024 · Novo Nordisk expects to file for regulatory approval of a label expansion for Rybelsus ® in both the US and EU around the turn of the year. The detailed results from SOUL will be presented at a scientific conference in 2025.